| Characteristic | Chinese originated assets* | Assets originated outside of China |
|---|---|---|
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Source
Release date
October 2025
More information
Region
Worldwide
Survey time period
as of October 2025
Supplementary notes
*Chinese assets include both for China only and for China and the U.S.
ADC = antibody-drug conjugate;Â
BsAb = bispecific antibody;
CAR-NK = chimeric antigen receptor-transduced natural killer cell;
CAR-T = chimeric antigen receptor T cell;
mAb = monoclonal antibody;
PROTAC = proteolysis-targeting chimera;
TCR-T = T-cell receptor therapy;
TIL = tumor-infiltrating lymphocyte.
Citation formats
